Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Interest Expenses (2021 - 2025)

Historic Interest Expenses for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to $10.5 million.

  • Autolus Therapeutics' Interest Expenses fell 155.34% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.0 million, marking a year-over-year decrease of 12419.83%. This contributed to the annual value of $9.3 million for FY2024, which is 7937.74% down from last year.
  • As of Q3 2025, Autolus Therapeutics' Interest Expenses stood at $10.5 million, which was down 155.34% from -$6.8 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Interest Expenses ranged from a high of $30.1 million in Q4 2023 and a low of -$30.8 million during Q4 2024
  • Over the past 5 years, Autolus Therapeutics' median Interest Expenses value was $5.0 million (recorded in 2023), while the average stood at $4.9 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first skyrocketed by 77150.71% in 2023, then crashed by 20234.67% in 2024.
  • Autolus Therapeutics' Interest Expenses (Quarter) stood at $1.1 million in 2021, then skyrocketed by 212.85% to $3.5 million in 2022, then surged by 771.51% to $30.1 million in 2023, then plummeted by 202.35% to -$30.8 million in 2024, then skyrocketed by 134.12% to $10.5 million in 2025.
  • Its Interest Expenses stands at $10.5 million for Q3 2025, versus -$6.8 million for Q2 2025 and $10.1 million for Q1 2025.